Diabetes Research and Clinical Practice
Volume 76, Issue 3 , Pages 358-367 , June 2007

Urinary PGDS levels are associated with vascular injury in type 2 diabetes patients

  • Ritsuko Yoshikawa

      Affiliations

    • Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, 2-5-1 Shikata-cho, Okayama 700-8558, Japan
    • ,
  • Jun Wada

      Affiliations

    • Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, 2-5-1 Shikata-cho, Okayama 700-8558, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 86 235 7235; fax: +81 86 222 5214.
    • ,
  • Kousuke Seiki

      Affiliations

    • Central Research Institute, Maruha Group Inc., Tsukuba, Japan
    • ,
  • Takashi Matsuoka

      Affiliations

    • Kurashiki Life Style Disease Center, Kurashiki, Japan
    • ,
  • Satoshi Miyamoto

      Affiliations

    • Diabetes Division, Department of Internal Medicine, Kurashiki Central Hospital, Kurashiki, Japan
    • ,
  • Kenji Takahashi

      Affiliations

    • Diabetes Division, Department of Internal Medicine, Kurashiki Central Hospital, Kurashiki, Japan
    • ,
  • Sachiko Ota

      Affiliations

    • Department of Medicine, Okayama Central Hospital, Okayama, Japan
    • ,
  • Kazuhi Taniai

      Affiliations

    • Department of Medicine, Okayama Central Hospital, Okayama, Japan
    • ,
  • Kazuyuki Hida

      Affiliations

    • Department of Medicine, National Hospital Organization Okayama Medical Center, Okayama, Japan
    • ,
  • Minoru Yamakado

      Affiliations

    • Health Service Center, Mitui Memorial Hospital, Tokyo, Japan
    • ,
  • Kenichi Shikata

      Affiliations

    • Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, 2-5-1 Shikata-cho, Okayama 700-8558, Japan
    • ,
  • Yoshio Uehara

      Affiliations

    • Health Service Center, University of Tokyo, Tokyo, Japan
    • ,
  • Yoshihiro Urade

      Affiliations

    • Department of Molecular Behavioral Biology, Osaka Bioscience Institute, Osaka, Japan
    • ,
  • Hirofumi Makino

      Affiliations

    • Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, 2-5-1 Shikata-cho, Okayama 700-8558, Japan

Received 19 May 2006 ,Accepted 4 September 2006.

References 

  1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595–1607
  2. Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch. Intern. Med. 1989;149(7):1514–1520
  3. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diab. Care. 1991;14(3):173–194
  4. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diab. Med. 1998;15(7):539–553
  5. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), JAMA 285 (19) (2001) 2486–2497.
  6. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286(4):421–426
  7. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106(14):1777–1782
  8. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen JS. Urinary albumin excretion. An independent predictor of ischemic heart disease. Arteriosc. Thromb. Vasc. Biol. 1999;19(8):1992–1997
  9. Roest M, Banga JD, Janssen WM, Grobbee DE, Sixma JJ, de Jong PE, et al. Excessive urinary albumin levels are associated with future cardiovascular mortality in postmenopausal women. Circulation. 2001;103(25):3057–3061
  10. Urade Y, Hayaishi O. Prostaglandin D synthase: structure and function. Vit. Horm. 2000;58:89–120
  11. Urade Y, Watanabe K, Hayaishi O. Prostaglandin D, E, and F synthases. J. Lipid Mediat. Cell Signal. 1995;12(2/3):257–273
  12. Hirawa N, Uehara Y, Ikeda T, Gomi T, Hamano K, Totsuka Y, et al. Urinary prostaglandin D synthase (beta-trace) excretion increases in the early stage of diabetes mellitus. Nephron. 2001;87(4):321–327
  13. Hamano K, Totsuka Y, Ajima M, Gomi T, Ikeda T, Hirawa N, et al. Blood sugar control reverses the increase in urinary excretion of prostaglandin D synthase in diabetic patients. Nephron. 2002;92(1):77–85
  14. Meigs JB, Wilson PW, Nathan DM, D’Agostino RB, Williams K, Haffner SM. Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes. 2003;52(8):2160–2167
  15. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diab. Care. 2001;24(4):683–689
  16. Bonora E, Targher G, Formentini G, Calcaterra F, Lombardi S, Marini F, et al. The metabolic syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diab. Med. 2004;21(1):52–58
  17. Isomaa B, Henricsson M, Almgren P, Tuomi T, Taskinen MR, Groop L. The metabolic syndrome influences the risk of chronic complications in patients with type II diabetes. Diabetologia. 2001;44(9):1148–1154
  18. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch. Intern. Med. 2004;164(10):1066–1076
  19. Malik S, Wong ND, Franklin SS, Kamath TV, L’Italien GJ, Pio JR, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004;110(10):1245–1250
  20. Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation. 2004;110(10):1251–1257
  21. Ninomiya JK, L’Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation. 2004;109(1):42–46
  22. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003;52(5):1210–1214
  23. Oda H, Shiina Y, Seiki K, Sato N, Eguchi N, Urade Y. Development and evaluation of a practical ELISA for human urinary lipocalin-type prostaglandin D synthase. Clin. Chem. 2002;48(9):1445–1453
  24. Kwon HM, Kim BJ, Lee SH, Choi SH, Oh BH, Yoon BW. Metabolic syndrome as an independent risk factor of silent brain infarction in healthy people. Stroke. 2006;37(2):466–470
  25. Vermeer SE, Hollander M, van Dijk EJ, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke. 2003;34(5):1126–1129
  26. Lempiainen P, Mykkanen L, Pyorala K, Laakso M, Kuusisto J. Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men. Circulation. 1999;100(2):123–128
  27. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288(21):2709–2716
  28. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S.. Diab. Care. 2005;28(11):2745–2749
  29. Matsumoto K, Miyake S, Yano M, Ueki Y, Yamaguchi Y, Akazawa S, et al. Glucose tolerance, insulin secretion, and insulin sensitivity in nonobese and obese Japanese subjects. Diab. Care. 1997;20(10):1562–1568
  30. Rutter MK, Meigs JB, Sullivan LM, D’Agostino RB, Wilson PW. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation. 2004;110(4):380–385
  31. Thomas GN, Lin JW, Lam WW, Tomlinson B, Yeung V, Chan JC, et al. Albuminuria is a marker of increasing intracranial and extracranial vascular involvement in type 2 diabetic Chinese patients. Diabetologia. 2004;47(9):1528–1534
  32. Yokoyama H, Aoki T, Imahori M, Kuramitsu M. Subclinical atherosclerosis is increased in type 2 diabetic patients with microalbuminuria evaluated by intima-media thickness and pulse wave velocity. Kidney Int. 2004;66(1):448–454
  33. Yuyun MF, Khaw KT, Luben R, Welch A, Bingham S, Day NE, et al. Microalbuminuria and stroke in a British population: the European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study. J. Intern. Med. 2004;255(2):247–256
  34. Martinez-Vea A, Salvado E, Bardaji A, Gutierrez C, Ramos A, Garcia C, et al. Silent cerebral white matter lesions and their relationship with vascular risk factors in middle-aged predialysis patients with CKD. Am. J. Kidney Dis. 2006;47(2):241–250
  35. Kobayashi S, Ikeda T, Moriya H, Ohtake T, Kumagai H. Asymptomatic cerebral lacunae in patients with chronic kidney disease. Am. J. Kidney Dis. 2004;44(1):35–41
  36. Hong CY, Chia KS, Ling SL. Urinary protein excretion in type 2 diabetes with complications. J. Diab. Complications. 2000;14(5):259–265
  37. Weitgasser R, Schnoell F, Gappmayer B, Kartnig I. Prospective evaluation of urinary N-acetyl-beta-d-glucosaminidase with respect to macrovascular disease in elderly type 2 diabetic patients. Diab. Care. 1999;22(11):1882–1886
  38. Eguchi Y, Eguchi N, Oda H, Seiki K, Kijima Y, Matsu-ura Y, et al. Expression of lipocalin-type prostaglandin D synthase (beta-trace) in human heart and its accumulation in the coronary circulation of angina patients. Proc. Natl. Acad. Sci. USA. 1997;94(26):14689–14694

PII: S0168-8227(06)00387-1

doi: 10.1016/j.diabres.2006.09.004

Diabetes Research and Clinical Practice
Volume 76, Issue 3 , Pages 358-367 , June 2007

Article Tools

* Image Usage & Resolution